Description
ZACTOSMR is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes (non-insulin-dependent diabetes mellitus, NIDDM).
ZACTOSMR is indicated as monotherapy.
ZACTOSMR is also indicated for use in combination with a sulfonylurea, metformin, an alpha-glucosidase inhibitor, or insulin, when diet and exercise, plus the single agent, do not give a good result in adequate glycemic control.
ZACTOSMR is also indicated for use in combination with a sulphonylurea and metformin (especially in overweight patients) when dual therapy with these drugs does not give good results in adequate glycemic control.
Management of type 2 diabetes should also include nutritional advice, weight reduction as needed, and exercise. These efforts are important not only in the primary treatment of type 2 diabetes, but also in maintaining the effectiveness of the drug.
After starting treatment with pioglitazone, patients should be evaluated every 3 to 6 months to ensure an adequate response to treatment (eg reduction in HbA1c). In patients who fail to show an adequate response, pioglitazone should be discontinued. Due to the potential risks with long-term treatment, it should be confirmed that the benefits of pioglitazone are sustained at subsequent routine visits.
Reviews
There are no reviews yet.